Lumbricus rubellus extract

Drug Profile

Lumbricus rubellus extract

Alternative Names: Disolf; DLBS-1033; Lumbricus low molecular weight proteins; Red earthworm extract

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dexa Medica
  • Class Alternative medicine; Enzymes; Thrombolytics; Traditional-Chinese-medicine
  • Mechanism of Action Fibrin inhibitors; Fibrinogen inhibitors; Fibrinolysis stimulants; Fibrinolytic agents; Janus kinase 1 inhibitors; Matrix metalloproteinase 9 inhibitors; NF-kappa B inhibitors; Platelet aggregation inhibitors; STAT1 transcription factor inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stroke
  • Phase II/III Acute coronary syndromes; Peripheral arterial disorders

Most Recent Events

  • 12 Feb 2017 Dexa Medica terminates a phase III trial in Stroke (Adjunctive treatment) in Indonesia (PO) (NCT02362984)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 Phase-II/III clinical trials in Acute coronary syndromes in Indonesia (PO) (NCT02976701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top